AnaptysBio Gets $1.5M from DARPA

Xconomy San Diego — 

San Diego’s AnaptysBio, which has been developing antibody-based technology with backing from Avalon Ventures, says it got a $1.5 million contract to develop military biosensors that could be used to detect specific biological agents in possible terrorist attacks. The Defense Advanced Research Projects Agency (DARPA) provided funding for the two-year effort, which will use Anaptys Bio’s proprietary somatic hypermutation (SHM) technology platform. Under a separate program, the NIH has provided funding to San Diego-based Trius Therapeutics to develop bioterror antibiotics.